Welcome to my Blog.... Mesothelioma

Abdominal Mesothelioma, Mesothelioma, Mesothelioma diagnosis, Mesothelioma Lawyer

==============================================================================

Friday, March 14, 2008

Fw: Unusual Features of Malignant Pleural Mesothelioma Metastatic to the Mediastinal Lymph Nodes.



----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:59 PM
Subject: Unusual Features of Malignant Pleural Mesothelioma Metastatic to the Mediastinal Lymph Nodes.

[1]Appl Immunohistochem Mol Morphol. 2008 Feb 8;
Wagner D, Bourne PA, Yang Q, Goldman BI, Lewis JS, Xu H

Malignant pleural mesothelioma (MPM) is a rare cancer that metastasizes to mediastinal lymph nodes (MLNs). The diagnosis of MPM metastatic to MLNs may not be straightforward. We describe 3 cases to highlight unusual entities of MPM metastatic to MLNs as follows. One patient with a history of T3N1M0, poorly differentiated esophageal adenocarcinoma and malignant melanoma presented with shortness of breath, mediastinal lymphadenopathy, and pleural effusion; metastatic disease was clinically suspected. Unexpectedly, immunohistochemical studies supported the diagnosis of MPM metastatic to the MLN on biopsy. In another case, mesothelial cell inclusions were initially diagnosed based on the light microscopy, immunohistochemistry, and lack of pleural thickening on computed tomography studies. Subsequent fine needle aspiration of an enlarged cervical lymph node found an atypical mesothelial proliferation, and metastatic mesothelioma was strongly suspected. Video-assisted thoracoscopic examination showed small visceral nodules, and pleural biopsy was diagnosed as malignant epithelioid mesothelioma. The mediastinal and cervical lymph node biopsies were reinterpreted as positive for MPM. In the last case, MLN biopsy showed a malignant epithelioid cell proliferation. Calretinin, CK5/6, WT-1, D2-40, p63, and CD5 were immunohistochemically detected in the tumor but epithelial markers and TTF-1 were negative. Metastatic mesothelioma was considered based on immunohistochemistry and computerized tomography finding of pleural thickening even though p63 and CD5 positivity were unusual. In summary, MPM may present as mediastinal lymphadenopathy with metastases or it may be a concurrent neoplasm with other malignancies or shows an unusual immunohistochemical staining pattern. Caution should be used when diagnosing mesothelial cell inclusions in MLNs.



___
Source: http://www.hubmed.org/display.cgi?uids=18301236
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 


Looking for last minute shopping deals? Find them fast with Yahoo! Search.

Fw: eComment: EPP and P/D: which to choose?



----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:59 PM
Subject: eComment: EPP and P/D: which to choose?

[1]Interact Cardiovasc Thorac Surg. 2008 Feb; 7(1): 106
Hasegawa S





___
Source: http://www.hubmed.org/display.cgi?uids=18234774
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 



Looking for last minute shopping deals? Find them fast with Yahoo! Search.

Fw: [New diagnostic markers for malignant pleural mesothelioma.]



----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:59 PM
Subject: [New diagnostic markers for malignant pleural mesothelioma.]

[1]Bull Cancer. 2008 Feb 28; 95(2): 177-184
Grigoriu BD, Grégoire M, Chahine B, Scherpereel A

The increasing number of malignant pleural mesothelioma (MPM) is a serious public health problem. The prognosis of this tumor is poor and most of the patients are diagnosed late in the disease's course when curative treatment is no more an option. It is therefore necessary to diagnose earlier MPM in these patients in order to obtain a potential significant improvement in survival. Some serum markers have been previously proposed for MPM diagnosis but none had sufficient sensitivity and specificity for being use in routine. Recently, soluble mesothelin and osteopontin have been proposed as diagnostic markers for mesothelioma. The authors reviewed recent data concerning the utility of these two molecules in the diagnosis and the treatment of MPM.. Mesothelin seems to be a specific marker for the epithelioid subtype of mesothelioma. Despite a good sensitivity, osteopontin has a low specificity for mesothelioma diagnosis. However, there is not enough data yet to propose guidelines on the use of these markers in a day to day practice.



___
Source: http://www.hubmed.org/display.cgi?uids=18304902
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 



Never miss a thing. Make Yahoo your homepage.

Fw: Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.



----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:59 PM
Subject: Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.

[1]Lung Cancer. 2008 Feb 25;
Metintas M, Ak G, Parspour S, Yildirim H, Erginel S, Alatas F, Batırel HF, Sivrikoz C, Metintas S, Dundar E

In malignant pleural mesothelioma (MPM) patients, local dissemination (LD) of the tumor is frequently observed at the sites of intervention where diagnosis/treatment are performed. We evaluate the factors affecting LD frequency and discuss the use of PR in MPM patients. Histopathologically diagnosed 212 MPM patients who had not received PR were evaulated in terms of development of LD. Of the 212 patients, 29 received supportive therapy, 157 received chemotherapy and 26 received multi-modal therapy. The LD frequency was 13.2% for all patients. The median survival rate was 9 or 10 months in patients with or without LD, respectively. A higher LD frequency was observed in patients receiving thoracotomy. The LD appearance time in supportive care is short. The LD frequency in patients treated with chemotherapy that revealed progressive disease was higher than the patients who revealed stable disease or objective response. LD developed in 2 months in patients with sarcomatous and mixed cell type, and the survival rate was low. LD was not associated with the stage of the disease. The most suitable candidate groups for PR are patients receiving supportive therapy, thoracotomy without multi-modal therapy or patients with sarcomatous and mixed cell type tumors.



___
Source: http://www.hubmed.org/display.cgi?uids=18304688
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 


Never miss a thing. Make Yahoo your homepage.

Thursday, March 13, 2008

Fwd: Mesothelioma Cancer Mouse Model Reproduces Human Disease



---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Thu, Mar 13, 2008 at 11:35 AM
Subject: Mesothelioma Cancer Mouse Model Reproduces Human Disease
To: mesothelioma77@gmail.com


HULIQ.com - Scientists have established a mouse model for human malignant mesothelioma (MM) that will provide valuable insight ... reproduces human disease Talcum powder stunts growth of lung tumors Chemo combination improves survival in asbestos-related cancer

Tue, 11 Mar 2008 19:13:00 GMT

___
Source: http://www.huliq.com/53288/mesothelioma-cancer-mouse-model-reproduces-human-disease
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Pathway Analysis of Microarray Data via Regression.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Mar 13, 2008 at 11:35 AM
Subject: Pathway Analysis of Microarray Data via Regression.
To: mesothelioma77@gmail.com


[1]J Comput Biol. 2008 Mar 10;
Adewale AJ, Dinu I, Potter JD, Liu Q, Yasui Y

Pathway analysis of microarray data evaluates gene expression profiles of a priori defined biological pathways in association with a phenotype of interest. We propose a unified pathway-analysis method that can be used for diverse phenotypes including binary, multiclass, continuous, count, rate, and censored survival phenotypes. The proposed method also allows covariate adjustments and correlation in the phenotype variable that is encountered in longitudinal, cluster-sampled, and paired designs. These are accomplished by combining the regression-based test statistic for each individual gene in a pathway of interest into a pathway-level test statistic. Applications of the proposed method are illustrated with two real pathway-analysis examples: one evaluating relapse-associated gene expression involving a matched-pair binary phenotype in children with acute lymphoblastic leukemia; and the other investigating gene expression in breast cancer tissues in relation to patients' survival (a censored survival phenotype). Implementations for various phenotypes are available in R. Additionally, an Excel Add-in for a user-friendly interface is currently being developed.



___
Source: http://www.hubmed.org/display.cgi?uids=18331198
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Lung metastases after liver resection or cryotherapy for hepatic metastasis from colorectal cancer-there is a difference!



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Mar 13, 2008 at 11:35 AM
Subject: Lung metastases after liver resection or cryotherapy for hepatic metastasis from colorectal cancer-there is a difference!
To: mesothelioma77@gmail.com


[1]HPB (Oxford). 2006; 8(2): 124-31
Yan TD, Chiang G, Zhao J, Chan D, Morris DL

Background. The most common site of colorectal extra-abdominal metastases is the lung. The relative risk of lung metastases after resection and cryotherapy has not previously been compared. Methods. All patients underwent an extensive preoperative staging including clinical examination, abdominal computed tomography (CT) and abdominal angio-CT to assess their hepatic disease. Two groups of patients were compared in this study (hepatic resection alone and hepatic cryotherapy with or without resection). A retrospective analysis of prospectively collected data was performed to assess the incidence and disease-free interval of pulmonary metastasis after surgical treatment of colorectal liver metastasis. Results. This paper clearly shows two differences regarding pulmonary metastases between patients treated with resection only and cryotherapy with or without resection. Among the 10 clinical variables, cryotherapy had the greatest correlation with pulmonary metastases (p=0.004). A patient who undergoes hepatic resection only has a probability of 35% for developing pulmonary recurrence, compared with 51% following cryotherapy. Cryotherapy was also independently associated with shorter pulmonary disease-free interval (p=0.036). Conclusion. There clearly is a higher risk of pulmonary metastasis after cryotherapy than after resection, whether this is related to selection of patients or a direct deleterious procedural effect requires more study.



___
Source: http://www.hubmed.org/display.cgi?uids=18333260
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Liver resection for hepatic metastases from adrenocortical carcinoma.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Mar 13, 2008 at 11:35 AM
Subject: Liver resection for hepatic metastases from adrenocortical carcinoma.
To: mesothelioma77@gmail.com


[1]HPB (Oxford). 2006; 8(2): 106-9
Carlo ID, Toro A, Sparatore F, Cordio S

Liver metastases from adrenocortical carcinoma are very rare and no clear indications for surgery exist. The aim of the present work was to define surgical indications for these neoplasms. All the patients submitted to hepatic resection for liver metastases from adrenal carcinoma reported in the literature (PubMed source) from 1978 to 2005 were considered for the present study. Forty-eight patients were found in the period of study, but it was only possible to obtain certain data for nine patients (18.7%). The data investigated suggest that metachronous metastases, developed after a minimum of 1 year from the primary tumor, and completely removable, may represent an indication for surgery - although this still needs to be proved.



___
Source: http://www.hubmed.org/display.cgi?uids=18333256
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Wednesday, March 12, 2008

Fwd: W.R. Grace to Pay for Cleanup of Asbestos Contamination in Libby, Montana (PR Newswire via Yahoo! News)



---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: W.R. Grace to Pay for Cleanup of Asbestos Contamination in Libby, Montana (PR Newswire via Yahoo! News)
To: mesothelioma77@gmail.com


W.R. Grace, a global supplier of specialty chemicals, has agreed to pay $250 million, the highest sum in the history of the Superfund program, to reimburse the federal government for the costs of the investigation and cleanup of asbestos contamination in Libby, Mont., the Justice Department and Environmental Protection Agency (EPA) announced today.

Tue, 11 Mar 2008 21:19:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=13r18o4p0/*http%3A//news.yahoo.com/s/usnw/20080311/pl_usnw/w_r__grace_to_pay_for_cleanup_of_asbestos_contamination_in_libby__montana
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: An 11-year retrospective study of totally implanted central venous access ports: Complications and patient satisfaction.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: An 11-year retrospective study of totally implanted central venous access ports: Complications and patient satisfaction.
To: mesothelioma77@gmail.com


[1]Eur J Surg Oncol. 2008 Mar 7;
Ignatov A, Hoffman O, Smith B, Fahlke J, Peters B, Bischoff J, Costa SD

AIMS: We wanted to assess the factors that predict complications and patient satisfaction of totally implanted central venous access ports (TIAP). METHODS: We reviewed 550 patients with breast or gynaecological malignancies who had initial port placement for chemotherapy between 1995 and 2006. We retrospectively assessed all TIAP complications, port duration and follow-up care until the TIAPs were removed (or the last known recorded documentation) or until the death of the patient. TIAP-related patient satisfaction was also assessed via a questionnaire-based survey of 356 patients. RESULTS: 561 TIAPs were placed in 550 cancer patients (11 patients received 2 TIAPs during the study period); the median time of port duration was 22.5months. There were 104 complications in this group. Of these, 81 occurred during chemotherapy treatment that lasted a median time of 182days. Removal secondary to complication was observed in 48 cases. TIAPs placed on the left chest side, through the subclavian vein or with the catheter tip localized in the peripheral part of superior vena cava demonstrated the highest incidence of complications. Patients with a BMI >28.75 had an increased risk for developing complications. Our follow-up questionnaire revealed a 93% patient satisfaction rate with the TIAP. CONCLUSIONS: Patients with left-sided ports, catheter tips lying in the upper part of the superior vena cava and implantation via the subclavian vein are at a higher risk for TIAP-associated complications. Being excessively overweight was assessed as another risk factor for developing complications. TIAPs are highly accepted and further recommended by patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18329836
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women.
To: mesothelioma77@gmail.com


[1]Hum Pathol. 2008 Mar 7;
Naqvi RA, Hussain A, Deo SS, Kukreti H, Chauhan M, Sarin R, Saxena A, Asim M, Shukla NK, Husain SA, Pasha ST, Basir SF

Alterations in protooncogenes and tumor-suppressor genes at the DNA and/or protein level, which indicate the biological properties of individual breast cancers, led us to design a study encompassing the dilemma of "epigenetic silencing-driven genomic instabilities." In this study, we analyzed the promoter methylation of potent mismatch repair genes (hmlh1 and hmsh2) for the first time in 232 Indian patients with primary breast cancer (using methylation-specific polymerase chain reaction and expressional analysis). The study evaluates the gamut of epigenetic aberrations as well as genomic instabilities (microsatellite instabilities and loss of heterozygosity) and includes analysis of BAT-25, BAT-26, D2S123, D5S346, and D17S250. We observed hypermethylation of the hmlh1 gene in 43.5% of patients with primary breast cancer, of whom 66.9% had locally advanced breast cancer (stage IIIA, IIIB, and IIIC) (P

___
Source: http://www.hubmed.org/display.cgi?uids=18329696
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Femara cuts cancer recurrence even if started late



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:26 PM
Subject: Femara cuts cancer recurrence even if started late
To: mesothelioma77@gmail.com


CHICAGO - Taking the breast cancer pill Femara can significantly reduce the chances that a woman's cancer will return, even long after she has stopped taking the estrogen blocker tamoxifen, ...

Tue, 11 Mar 2008 22:32:34 GMT


Source: http://today.reuters.com/news/NewsArticle.aspx?storyID=2008-03-10T221439Z_01_N10497705_RTRUKOC_0_US-CANCER-BREAST-FEMARA.xml
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Grace to Pay Feds for Montana Cleanup



---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: Grace to Pay Feds for Montana Cleanup
To: mesothelioma77@gmail.com


Forbes - Asbestos from Grace's former vermiculite mine near the town has been blamed for cases of lung-scarring asbestosis and for mesothelioma, a fast-moving cancer that attacks the lungs.

Tue, 11 Mar 2008 23:59:00 GMT

___
Source: http://www.forbes.com/feeds/ap/2008/03/11/ap4760476.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Developer Could Face Fines For Asbestos Handling (KCCI 8 Des Moines)



---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: Developer Could Face Fines For Asbestos Handling (KCCI 8 Des Moines)
To: mesothelioma77@gmail.com


A company owned by Des Moines real estate developer Bob Knapp could face fines after investigators said the company failed to follow rules about how to remove asbestos at the Equitable Building.

Tue, 11 Mar 2008 03:28:33 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=122agjg4q/*http%3A//www.kcci.com/news/15557393/detail.html?rss=des&psp=news
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Asbestos fear at Oak St. Beach



---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: Asbestos fear at Oak St. Beach
To: mesothelioma77@gmail.com


Chicago Sun-Times - Oak Street Beach needs to be retested for asbestos because previous tests for the cancer-causing substance weren't done properly, a scientist on the U.S. Environmental Protection Agency's asbestos advisory board is urging. "They should go back and ...

Tue, 11 Mar 2008 08:50:00 GMT

___
Source: http://www.suntimes.com/news/metro/835394,CST-NWS-asbes11.article
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: A hard look



---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: A hard look
To: mesothelioma77@gmail.com


Hibbing Daily Tribune - PAUL — "Does taconite produce asbestos-like fibers that endanger our miners and their families," asked Rep. ... million in general fund money to spearhead the research that will take a hard look at mesothelioma, a form of lung cancer ...

Mon, 10 Mar 2008 00:59:00 GMT

___
Source: http://www.hibbingmn.com/articles/2008/03/11/news/doc47d48e742c06a635198655.txt
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Mike Huckabee (R)



---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: Mike Huckabee (R)
To: mesothelioma77@gmail.com


Henderson Daily News - ... then he passed away within a year of being diagnosed," she said. "I also lost my grandmother to cancer and my newfound passion is my dad - he was recently diagnosed with malignant mesothelioma, the one caused by asbestos. It is a terminal cancer ...

Mon, 10 Mar 2008 18:53:00 GMT

___
Source: http://www.hendersondailynews.com/articles/2008/03/10/news/03relaystorysun.txt
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Mouse model for human malignant mesothelioma



---------- Forwarded message ----------
From: Live Search News: asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: Mouse model for human malignant mesothelioma
To: mesothelioma77@gmail.com


News-Medical.Net - MM is an aggressive cancer originating from the mesothelial lining of the pleural cavity. MM is associated with asbestos exposure and is characterized by a long latency period between exposure and disease onset.

Tue, 11 Mar 2008 10:16:00 GMT

___
Source: http://www.news-medical.net/?id=36109
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients.



---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients.
To: mesothelioma77@gmail.com


[1]J Thorac Cardiovasc Surg. 2008 Mar; 135(3): 620-626.e3
Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW

OBJECTIVE: The optimal procedure for resection of malignant pleural mesothelioma is controversial, partly because previous analyses include small numbers of patients. We performed a multi-institutional study to increase statistical power to detect significant differences in outcome between extrapleural pneumonectomy and pleurectomy/decortication. METHODS: Patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy or pleurectomy/decortication at 3 institutions were identified. Survival and prognostic factors were analyzed by the Kaplan-Meier method, log-rank test, and Cox proportional hazards analysis. RESULTS: From 1990 to 2006, 663 consecutive patients (538 men and 125 women) underwent resection. The median age was 63 years (range, 26-93 years). The operative mortality was 7% for extrapleural pneumonectomy (n = 27/385) and 4% for pleurectomy/decortication (n = 13/278). Significant survival differences were seen for American Joint Committee on Cancer stages 1 to 4 (P

___
Source: http://www.hubmed.org/display.cgi?uids=18329481
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Equitable Building asbestos case referred to A.G. (The Des Moines Register)



---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: Equitable Building asbestos case referred to A.G. (The Des Moines Register)
To: mesothelioma77@gmail.com


Developer Bob Knapp didn't appear before a board investigating allegations of asbestos in the 84-year-old building where he wants to build condos.

Tue, 11 Mar 2008 19:05:53 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12m3qh789/*http%3A//www.desmoinesregister.com/apps/pbcs.dll/article?AID=/20080311/NEWS/80311024
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: W.R. Grace agrees to pay for Libby asbestos clean up (KTVQ Billings)



---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Mar 11, 2008 at 10:27 PM
Subject: W.R. Grace agrees to pay for Libby asbestos clean up (KTVQ Billings)
To: mesothelioma77@gmail.com


W.R. Grace is agreeing to pay out the largest settlement in federal Superfund history, reimbursing the federal government $250-million for cleaning up cancer-causing asbestos in Libby.

Tue, 11 Mar 2008 21:08:05 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=121lg6a07/*http%3A//www.montanasnewsstation.com/global/story.asp?s=8000111
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Mario Winans - Thats The Thanks I Get - music tone



---------- Forwarded message ----------
From: YouTube :: Tag // life insrance <rssfwd@rssfwd.com>
Date: Wed, Mar 5, 2008 at 1:03 AM
Subject: Mario Winans - Thats The Thanks I Get - music tone
To: collegeschoolloan@gmail.com


[1]

Get the ringtone: http://www.ringtonegal.com/Mario-Winans/Thats-The-Thanks-I-Get Full Song Lyrics: Intro - Mario Winans Yo yeah Yeah yo yo yo, c'mon Yeah, this is 'Rio Yeah 'Rio Winans Yeah mmm mmmm, mmm mmmm, mmm mmmm You hurt me so bad Mmm hmmm, baby, yeah Verse - Mario Winans I always trusted you bet that all It didn't mean that much to you, babe I gave my love love my time my time and my life In return you give me pain oh yeah What a shame oh babe and this is the thanks I get baby Chorus - Mario Winans How could you do it to a nigga like this Tell me, tell me oh yeah And why would you give another nigga my kiss oh baby You hurt me, hurt me babe I gave my love love my time my time my life oh baby In return you give me pain oh yeah What a shame oh baby and this is the thanks I get baby Bridge This is 'Rio 'Rio Winans Mmm mmmm, mmm mmmm, mmm mmmm This Is the Thanks I Get ringtones on http://www.ringtonegal.com/Mario-Winans/Thats-The-Thanks-I-Get You hurt me so bad Mmm hmmm, baby, now verse two Verse - Mario Winans I believed in everything babe bet that all Until the day you lied to me, girl I gave my heart my heart my mind my mind my soul oh baby In return you give me pain oh yeah What a shame oh yeah and this is the thanks I get baby Chorus - Mario Winans How could you do it to a nigga like this Tell me, tell me oh yeah And why would you give another nigga my kiss oh baby You hurt me, hurt me babe I gave my love my love my time my time my life oh baby In return you give me pain oh baby What a shame, and this is the thanks I get baby Verse - Black Rob Ever since he met you had that good Oochie Wally Curves so killer, you put insurance on your body Remember that jude joints your hair all knotty And I

Author: [2]Justine56768111
Keywords: [3]intro [4]mario [5]winans [6]yo [7]yeah [8]cmon [9]this [10]is [11]rio [12]mmm [13]mmmm [14]you [15]hurt [16]me [17]so [18]bad [19]hmmm [20]baby [21]verse [22]always [23]trusted [24]bet [25]that [26]all [27]it [28]didnt [29]mean [30]much
Added: March 3, 2008


rss@youtube.com (Justine56768111) Mon, 03 Mar 2008 19:51:20 -0800

* Attachment, application/x-shockwave-flash: [31]Download
___
Source: http://youtube.com/?v=os2ff0dgdNc
--
 Powered by [35]RssFwd, a service of [36]Blue Sky Factory, Inc

 

Tuesday, March 11, 2008

Fwd: Evaluation of the Branched-Chain DNA Assay for Measurement of RNA in Formalin-Fixed Tissues.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Evaluation of the Branched-Chain DNA Assay for Measurement of RNA in Formalin-Fixed Tissues.
To: mesothelioma77@gmail.com


[1]J Mol Diagn. 2008 Feb 14;
Knudsen BS, Allen AN, McLerran DF, Vessella RL, Karademos J, Davies JE, Maqsodi B, McMaster GK, Kristal AR

We evaluated the branched-chain DNA (bDNA) assay QuantiGene Reagent System to measure RNA in formalin-fixed, paraffin-embedded (FFPE) tissues. The QuantiGene Reagent System does not require RNA isolation, avoids enzymatic preamplification, and has a simple workflow. Five selected genes were measured by bDNA assay; quantitative polymerase chain reaction (qPCR) was used as a reference method. Mixed-effect statistical models were used to partition the overall variance into components attributable to xenograft, sample, and assay. For FFPE tissues, the coefficients of reliability were significantly higher for the bDNA assay (93-100%) than for qPCR (82.4-95%). Correlations between qPCRFROZEN, the gold standard, and bDNAFFPE ranged from 0.60 to 0.94, similar to those from qPCRFROZEN and qPCRFFPE. Additionally, the sensitivity of the bDNA assay in tissue homogenates was 10-fold higher than in purified RNA. In 9- to 13-year-old blocks with poor RNA quality, the bDNA assay allowed the correct identification of the overexpression of known cancer genes. In conclusion, the QuantiGene Reagent System is considerably more reliable, reproducible, and sensitive than qPCR, providing an alternative method for the measurement of gene expression in FFPE tissues. It also appears to be well suited for the clinical analysis of FFPE tissues with diagnostic or prognostic gene expression biomarker panels for use in patient treatment and management.



___
Source: http://www.hubmed.org/display.cgi?uids=18276773
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Bayer halts trial of lung cancer treatment (TODAYonline)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 8:35 AM
Subject: Bayer halts trial of lung cancer treatment (TODAYonline)
To: mesothelioma77@gmail.com


Bayer logo on a building in Berlin. German drug group Bayer said Monday that it had halted trials of its leading cancer treatment Nexavar for one of the main forms of lung cancer.

Mon, 18 Feb 2008 19:37:12 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11iodpo89/*http%3A//www.todayonline.com/articles/238295.asp
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: LegalView Offers Traumatic Brain Injury Victims Information on New Interview Technique To Restore Long-Term Memory ... (PRWeb)



---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma <rssfwd@rssfwd.com>
Date: Sun, Feb 17, 2008 at 6:00 PM
Subject: LegalView Offers Traumatic Brain Injury Victims Information on New Interview Technique To Restore Long-Term Memory ... (PRWeb)
To: mesothelioma77@gmail.com


LegalView reports a new scientific research on an interviewing technique that will help traumatic brain injury patients retrieve long-term memory. LegalView discovered the recent study on the autobiographic interview technique, which is helping brain injury victims with memory impairment. (PRWeb Feb 17, 2008) Read the full story at http://www.prweb.com/releases/2008/02/prweb703693.htm

Sun, 17 Feb 2008 08:18:14 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma/SIG=11p33u2ns/*http%3A//www.prweb.com/releases/2008/02/prweb703693.htm
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
To: mesothelioma77@gmail.com


[1]Cell Cycle. 2008 Feb 11; 7(5):
Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T

Cancer cell lines are essential tools used in many areas of biomedical research. Using the last release of the UMD_p53 database (2007)(1), we analysed the p53 status of 1,211 cell lines published between 1989 and 2007. p53 mutations in cell lines from various types of cancers display a striking similarity in the distribution of mutations and in the pattern of mutational events compared to tumours, indicating that they are representative of the cells from which they were derived. Analysis of the residual transcriptional activity of p53 mutants identified in cell lines that displayed two different p53 mutations show that there is a high frequency of weak mutations that are paired with more potent mutations suggesting a driver / passenger configuration. Strikingly, we found discrepancies in the p53 status for 23% (88/384) of cell lines, for which the p53 status was established.



___
Source: http://www.hubmed.org/display.cgi?uids=18277095
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Unusual Features of Malignant Pleural Mesothelioma Metastatic to the Mediastinal Lymph Nodes.



----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, February 28, 2008 2:03:45 PM
Subject: Unusual Features of Malignant Pleural Mesothelioma Metastatic to the Mediastinal Lymph Nodes.

[1]Appl Immunohistochem Mol Morphol. 2008 Feb 8;
Wagner D, Bourne PA, Yang Q, Goldman BI, Lewis JS, Xu H

Malignant pleural mesothelioma (MPM) is a rare cancer that metastasizes to mediastinal lymph nodes (MLNs). The diagnosis of MPM metastatic to MLNs may not be straightforward. We describe 3 cases to highlight unusual entities of MPM metastatic to MLNs as follows. One patient with a history of T3N1M0, poorly differentiated esophageal adenocarcinoma and malignant melanoma presented with shortness of breath, mediastinal lymphadenopathy, and pleural effusion; metastatic disease was clinically suspected. Unexpectedly, immunohistochemical studies supported the diagnosis of MPM metastatic to the MLN on biopsy. In another case, mesothelial cell inclusions were initially diagnosed based on the light microscopy, immunohistochemistry, and lack of pleural thickening on computed tomography studies. Subsequent fine needle aspiration of an enlarged cervical lymph node found an atypical mesothelial proliferation, and metastatic mesothelioma was strongly suspected. Video-assisted thoracoscopic examination showed small visceral nodules, and pleural biopsy was diagnosed as malignant epithelioid mesothelioma. The mediastinal and cervical lymph node biopsies were reinterpreted as positive for MPM. In the last case, MLN biopsy showed a malignant epithelioid cell proliferation. Calretinin, CK5/6, WT-1, D2-40, p63, and CD5 were immunohistochemically detected in the tumor but epithelial markers and TTF-1 were negative. Metastatic mesothelioma was considered based on immunohistochemistry and computerized tomography finding of pleural thickening even though p63 and CD5 positivity were unusual. In summary, MPM may present as mediastinal lymphadenopathy with metastases or it may be a concurrent neoplasm with other malignancies or shows an unusual immunohistochemical staining pattern. Caution should be used when diagnosing mesothelial cell inclusions in MLNs.



___
Source: http://www.hubmed.org/display.cgi?uids=18301236
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 


Looking for last minute shopping deals? Find them fast with Yahoo! Search.

Fwd: Onyx Halts Lung Cancer Study (TheStreet.com)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 8:35 AM
Subject: Onyx Halts Lung Cancer Study (TheStreet.com)
To: mesothelioma77@gmail.com


There were hopes for as much as $1 billion in additional revenue from nexavar as lung cancer treatment.

Tue, 19 Feb 2008 12:05:11 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=13avrl3lh/*http%3A//www.thestreet.com/s/onyx-halts-lung-cancer-study/newsanalysis/biotech/10403855.html?puc=_tscrss
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Multiple Primary Tumors in Differentiated Thyroid Carcinoma and Relationship to Thyroid Cancer Outcome.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Multiple Primary Tumors in Differentiated Thyroid Carcinoma and Relationship to Thyroid Cancer Outcome.
To: mesothelioma77@gmail.com


[1]Endocr J. 2008 Feb 15;
Omür O, Ozcan Z, Yazıcı B, Akgün A, Oral A, Ozkılıç H

Patients with differentiated thyroid carcinoma (DTC) have long-life expectancy and are at risk for developing a second primary cancer. Aim of this study was to assess the occurrence of DTC in conjunction with other primary neoplasms. It was also aimed to explore the possibility of synchronous or metachronous other malignancies having an impact on clinical course of thyroid carcinoma. Clinical records of 1680 DTC patients treated and followed in our institution over last twenty years were reviewed. Forty-five second primary tumors were found in 42 patients. These patients were classified into 3 groups as antecedent (group I), synchronous (group II) or subsequent (group III) according to the timing of occurrence of non-thyroidal malignancy. The initial characteristics of thyroid neoplasm were compared between patients with DTC plus another tumor and DTC only. Kaplan-Meier Survival Analysis was used to estimate the survival probability for patients with DTC alone and DTC plus another primary tumor. There were 15 synchronous and 30 metachronous tumors in 42 patients. Three of them had triple tumors. The most common second primary was lympho-haematological and upper aero digestive system tumors in group I and II respectively, whereas a variety of tumors were noted in group III. Despite the more common occurrence of unfavourable prognostic factors in patients with multiple cancers than thyroid cancer alone, complete response to radioiodine therapy and recurrence free survival rate was similar in both groups (p>0,05). The results of the current series imply that the occurrence of multiple primary tumors is not uncommon in patients with DTC. Close medical surveillance and the use of advanced screening modalities might lead to the detection of second primary tumors in DTC. However, the presence of second primary seems not to affect the clinical course of DTC.



___
Source: http://www.hubmed.org/display.cgi?uids=18277003
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Reuniting?



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Feb 17, 2008 at 6:11 PM
Subject: Reuniting?
To: mesothelioma77@gmail.com


Filed under: Anglophilia > Lily Allen The walk of shame! Lily Allen was seen leaving a fella's house in London on Sunday morning.

Sun, 17 Feb 2008 19:02:48 GMT


Source: http://perezhilton.com/2008-02-17-reuniting
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Timeline: Kosovo



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Feb 17, 2008 at 6:11 PM
Subject: Timeline: Kosovo
To: mesothelioma77@gmail.com


A chronology of key events 12th century - Kosovo lies at the heart of the Serbian empire, under the Nemanjic dynasty.

Sun, 17 Feb 2008 19:59:21 GMT


Source: http://news.bbc.co.uk/1/hi/world/europe/country_profiles/3550401.stm
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Monday, March 10, 2008

Fwd: Study Finds Cancer Diagnosis Linked to Insurance (New York Times)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Feb 18, 2008 at 10:04 AM
Subject: Study Finds Cancer Diagnosis Linked to Insurance (New York Times)
To: mesothelioma77@gmail.com


A nationwide study has found that the uninsured and those covered by Medicaid are more likely than those with private insurance to receive a diagnosis of cancer in the late stages of the disease.

Mon, 18 Feb 2008 00:19:33 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11q7rskv7/*http%3A//www.nytimes.com/2008/02/18/health/18cancer.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Bayer halts trial of lung cancer treatment (AFP via Yahoo! News)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 8:35 AM
Subject: Bayer halts trial of lung cancer treatment (AFP via Yahoo! News)
To: mesothelioma77@gmail.com


German drug group Bayer said Monday that it had halted trials of its leading cancer treatment Nexavar for one of the main forms of lung cancer.

Mon, 18 Feb 2008 18:26:18 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12timsgd0/*http%3A//news.yahoo.com/s/afp/20080218/hl_afp/germanypharmacompanyproductbayer_080218182618
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Key Trends for the Global Cancer Market



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Feb 19, 2008 at 8:35 AM
Subject: Key Trends for the Global Cancer Market
To: mesothelioma77@gmail.com


Reportlinker.com announces that a new market research report related to the Oncology market is available in its catalogue.

Tue, 19 Feb 2008 10:25:34 GMT


Source: http://www.businesswire.com/portal/site/home/index.jsp?viewID=news_view&beanID=1024816846&newsId=20080219005710&ndmHsc=v2*A1203426000000*B1203445414000*DgroupByDate*J1*N1010492&epi-content=GENERIC
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Calorie restriction and cardiometabolic health.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Calorie restriction and cardiometabolic health.
To: mesothelioma77@gmail.com


[1]Eur J Cardiovasc Prev Rehabil. 2008 Feb; 15(1): 3-9
Fontana L

An epidemic of overweight/obesity and type 2 diabetes, caused by overeating nutrient-poor energy-dense foods and a sedentary lifestyle, is spreading rapidly throughout the world. Abdominal obesity represents a serious threat to health because it increases the risk of developing many chronic diseases, including cardiovascular disease and cancer. Calorie restriction (CR) with adequate nutrition improves cardiometabolic health, prevents tumorigenesis and increases life span in experimental animals. The purpose of this review is to evaluate the metabolic and clinical implications of CR with adequate nutrition in humans, within the context of data obtained in animal models. It is unlikely that information regarding the effect of CR on maximal life span in humans will become available in the foreseeable future. In young and middle-aged healthy individuals, however, CR causes many of the same cardiometabolic adaptations that occur in long-lived CR rodents, including decreased metabolic, hormonal and inflammatory risk factors for diabetes, hypertension, cardiovascular disease and cancer. Unraveling the mechanisms that link calorie intake and body composition with metabolism and aging will be a major step in understanding the age-dependency of a wide range of human diseases and will also contribute to improve the general quality of life at old ages.



___
Source: http://www.hubmed.org/display.cgi?uids=18277179
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Gene Expression Profiling Advance for Lung Cancer Prognosis (Newswise)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Gene Expression Profiling Advance for Lung Cancer Prognosis (Newswise)
To: mesothelioma77@gmail.com


Mayo Clinic Cancer Center researchers have identified two non-cell type-specific gene expression biomarker profiles that provide improved survival prediction for non-small-cell lung cancer. Their findings will be published in the Feb. 20 issue of the Journal of Clinical Oncology.

Fri, 15 Feb 2008 23:26:48 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11p5iipnh/*http%3A//www.newswise.com/articles/view/537713/?sc=rsmn
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc
 

Sunday, March 9, 2008

Fw: Biological characteristics of cancers involving the serosal cavities.



----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Wednesday, February 27, 2008 7:16:13 PM
Subject: Biological characteristics of cancers involving the serosal cavities.

[1]Crit Rev Oncog. 2007; 13(3): 189-227
Davidson B

The presence of cancer cells in effusions within the serosal (peritoneal, pleural, and pericardial) cavities is a clinical manifestation of advanced-stage cancer and is associated with poor survival. Tumor cells in effusions most frequently originate from primary carcinomas of the ovary, breast, and lung, and from malignant mesothelioma, a native tumor of this anatomic site. Unlike the majority of solid tumors, particularly at the primary site, cancer cells in effusions are not amenable to surgical removal and failure in their eradication is one of the main causes of treatment failure. In recent years, we have studied the biological characteristics of ovarian carcinoma, breast carcinoma, and malignant mesothelioma cells in effusions and compared it to their counterparts in primary tumors and solid metastases. Our data show that a large number of cancer-associated molecules, including cell adhesion proteins, proteolytic enzymes, growth factor receptors, signaling molecules, and transcription factors, are differentially expressed along tumor progression and have a different prognostic value, depending on the organ sampled. In ovarian carcinoma, several of these molecules are differentially expressed in primary diagnosis (prechemotherapy) and disease recurrence (postchemotherapy) specimens, reflecting the effect of disease progression and chemotherapy, and have different prognostic significance as function of disease progression. The findings presented in this review underscore the need to take into consideration the unique biology of cancer cells in effusions if patient-tailored molecular therapy is to become a successful treatment modality in these malignancies.



___
Source: http://www.hubmed.org/display.cgi?uids=18298385
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 


Never miss a thing. Make Yahoo your homepage.

Fwd: Small Retail: It's the inner glow that sells handblown glassybabys



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Small Retail: It's the inner glow that sells handblown glassybabys
To: mesothelioma77@gmail.com


THERE'S SOMETHING sensual and slightly improbable about glassybabys, the handblown, color-saturated tumblers that have become darlings of the design world.

Sat, 16 Feb 2008 15:26:10 GMT


Source: http://seattlepi.nwsource.com/business/351463_retail16.html?
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: More advanced cancer seen in uninsured Americans (Reuters via Yahoo! News)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Feb 18, 2008 at 10:04 AM
Subject: More advanced cancer seen in uninsured Americans (Reuters via Yahoo! News)
To: mesothelioma77@gmail.com


Uninsured Americans and those in a government health program for the poor are far more likely to have advanced diseases when diagnosed with cancer than those with private coverage, researchers said on Sunday.

Mon, 18 Feb 2008 06:30:53 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11tubscdl/*http%3A//news.yahoo.com/s/nm/20080218/hl_nm/cancer_usa_dc_1
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
To: mesothelioma77@gmail.com


[1]Breast Cancer. 2008 Feb 15;
Nagasaki K, Miki Y

Breast cancer is considered to be relatively sensitive to chemotherapy, and multiple combinations of cytotoxic agents are used as standard therapy. Chemotherapy is applied empirically despite the observation that not all regimens are equally effective across the population of patients. Up to date clinical tests for predicting cancer chemotherapy response are not available, and individual markers have shown little predictive value. A number of microarray studies have demonstrated the use of genomic data, particularly gene expression signatures, as clinical prognostic factors in breast cancer. The identification of patient subpopulations most likely to respond to therapy is a central goal of recent personalized medicine. We have designed experiments to identify gene sets that will predict treatment-specific response in breast cancer. Taken together with our recent trial about the construction of a high-throughput functional screening system for chemo-sensitivity related genes, studies for drug sensitivity will provide rational strategies for establishment of the prediction system with high accuracy, and identification of ideal targets for drug intervention.



___
Source: http://www.hubmed.org/display.cgi?uids=18274834
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Got Green Tea? If Not, You Should



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Got Green Tea? If Not, You Should
To: mesothelioma77@gmail.com


Green tea just may be nature's best safety net against cancer, heart disease, and signs of aging.

Sat, 16 Feb 2008 13:42:30 GMT


Source: http://www.redorbit.com/news/health/1256993/got_green_tea_if_not_you_should/index.html
--
  ~
Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Capitol Waste Services, Inc. Pays $107,300 for Excessive Idling



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 8:08 PM
Subject: Capitol Waste Services, Inc. Pays $107,300 for Excessive Idling
To: mesothelioma77@gmail.com


Capitol Waste Services, Inc. Pays $107,300 for Excessive Idling An eastern Massachusetts waste hauler has recently paid an EPA penalty of $107,300 for exceeding the state idling limit in Massachusetts.

Sat, 16 Feb 2008 16:37:19 GMT


Source: http://envirovaluation.org/index.php/2008/02/16/capitol_waste_services_inc_pays_107_300_
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc